Ketone supplementation

PreclinicalSmall molecule

Ketone supplementation is one of 2 small molecule programs targeting Caloric Restriction. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Caloric RestrictionCompleted

Caloric RestrictionPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Caloric Restriction

#DrugCompanyPhaseTrials

Bisphosphonate

Amgen

Phase 3

1 2

Ketone supplementation

VVanderbilt University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Delirium

NCT07364162

Clinical

Trials by Indication[1]

Caloric Restriction1 trial

Effects of Ketones on Muscle Wasting During Caloric Restriction in Lean Females

Completed·KKU Leuven·N/A·NCT04744142·44 enrolled

Delirium1 trial

Exogenous Ketone Ester Supplementation in ICU Delirium (KETONES ICU)

Recruiting·VVanderbilt University Medical Center·Phase 2·NCT07364162·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ketone supplementation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ketone supplementation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ketone supplementation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt University Medical Center

Ketone supplementation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Caloric Restriction1 trial

Delirium1 trial

References

Drug Info

Quick Facts

Related News